ANKE BIO(SZ:300009)2022-12-07 08:38Group 1: Company Development Strategy - The company has restructured its development plan since 2014, investing in Xinhuakun Biotechnology to develop recombinant human freeze-dried keratinocyte growth factor (KGF-2), currently in Phase III clinical trials [4] - Health products utilizing biological growth factor technology, such as masks and serums, have been launched and are selling well [4] - The company has successfully acquired Shanghai Suhao Yiming Pharmaceutical Co., Ltd. and is focusing on precision medicine technologies like gene testing and cell therapy [4][6] Group 2: Financial Performance - The company has maintained stable and healthy growth, exceeding the planned profit growth rate of 20% [5] - Historical data shows that growth hormone sales have increased by over 30% annually, while interferon sales have grown by approximately 15% [5] Group 3: Product Development - Xinhuakun has developed pharmaceutical cosmetics, including masks and serums, which were initially sold internally and are now expanding to external sales due to positive feedback [5] - The company plans to introduce more series of products in the future [5] Group 4: Collaboration and Market Expansion - Zhongde Meilian, founded by returnees from the U.S., focuses on forensic diagnostics and is expanding into the gene testing field [6] - The company has established partnerships with public security agencies to provide technical services and is expanding its regional collaborations [6] Group 5: Future Development Strategy - The company aims to position itself in the biopharmaceutical sector, continuing to invest in competitive products and companies [6] - Future collaborations with scientists from Boshengji and Zhongde Meilian will enhance the company's market competitiveness and influence [6]